The programme is designed to support early-stage biotech companies in getting their biologic or cell & gene therapy products and technologies to market
A new survey reveals deep scepticism toward AI-generated regulatory materials, with pharma teams citing hallucinations, poor auditability and lack of transparency as major risks
Get breaking news, product releases, technical papers, innovation features, trend reports and live content agendas covering the entire industry.